Furthermore, research has indicated that PG 97-269 may reduce the production of cytokines (IL-1β and IL-6) by immune cells, such as monocytes, mast cells, and macrophages, whereas it also inhibits their chemotactic activity, thus holding therapeutic potential in the treatment of colitis [61]. Here, IL6 is linked to colitis.